1986 Volume 89 Issue 6 Pages 744-753
Activation of peripheral blood lymphocytes (PBL) from patients with head and neck malignant tumors in human recombinant interleukin 2 (rIL-2) containing complete medium were tried for expression of the lymphokine activated killer (LAK) cells. The cytotoxic activity toward human maxillary sinus carcinoma cell line (OKK-1), human laryngeal carcinoma cell line (LCT-6) and fresh autologous carcinoma cells were tested in 5 hours 51chromium release assay.
Anti-tumor efficacy of LAK cells and rIL-2 administration to the BALB/c nu/nu mice transplanted LCT-6 carcinoma were observed.
The results obtained were as follows:
1. Lymphokine activated killer cells from patients with head and neck malignant tumors or normal individuals resulted in expression of cytotoxicity toward OKK-1, LCT-6 cell lines.
2. Fresh solid maxillary sinus carcinoma cells were resistant to autologous fresh PBL, but were lysed by autologous LAK cells.
3. Local transfer of human LAK cells plus systemic rIL-2 administration could mediate the restriction of tumor growth and the elongation of survival rate in LCT-6 transplanted mice.(p<0.05) No restriction of tumor growth was observed in any of these mice treated with either LAK cells alone or rIL-2 alone.
